Back to News
Market Impact: 0.3
Ultragenyx Pharmaceutical Inc. Completes $210 million PRV Sale and Announces Restructuring Plan to Reduce 2027 Expenses
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsM&A & Restructuring
On October 30, 2026, Ultragenyx Pharmaceutical completed the sale of its GENGLYCOS Rare Pediatric Disease Priority Review Voucher. The company received $210 million in gross proceeds at closing; the article provides no further details on the transaction's financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
RARE0.55
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- China Blocks SoftBank Acquisition of ABB Robot Unit, FT Says
- Snap shares fall over 10% on third-quarter earnings miss
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales
- Drone Attacks Spawn New Insurance Market in Baltics, Poland